Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Next Previous
Trial Profile

Phase 3, Randomized, Double-blind, Placebo-controlled, Trial With an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder (HSDD)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 28 Mar 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bremelanotide (Primary)
  • Indications Decreased libido; Female sexual dysfunction
  • Focus Therapeutic Use
  • Acronyms HSDD; RECONNET
  • Sponsors Palatin Technologies

Most Recent Events

  • 01 Mar 2022 Results of this study and the extension study assessing pre-specified and sub-group analysis assessing efficacy of bremelanotide were published in the Journal of Women's Health.
  • 27 Apr 2020 Results effect of bremelanotide on ambulatory blood pressure when administered for up to 16 consecutive days, presented at the 69th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists.
  • 16 Oct 2019 According to a Palatin Technologies media release, data from RECONNECT trials will be presented by Sheryl Kingsberg at the 13th European Society of Gynecology Conference 2019. The conference and the data presentations are jointly sponsored by Palatin and AMAG Pharmaceuticals, Inc.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top